New Treatment Implications For Ovarian Cancer Unveiled
medicalnewstoday.com     May 17, 2008            

New research findings from a top clinical investigator at The Cancer Institute of New Jersey (CINJ) indicate the potential for more targeted treatment of ovarian cancer, which is expected to claim more than 15,000 lives nationwide this year, with 480 in New Jersey. [read full story]                    


View all news articles about*:
Ambulatory America ASCO Cancers Care Discoveries Female gynaecology Health Jersey Medical North Obstetrics Oncology Patients Research Scientific States United
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

Vion Pharmaceuticals signs agreement with Hovon for Phase III cancer trial

pharmaceutical-business-review.com     11 hrs ago   6 related          

Vion Pharmaceuticals has signed an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology to conduct a clinical trial of laromustine with standard remission-induction therapy in patients aged 18-65...                    

comments

Eli Lilly acquires SGX Pharmaceuticals

news-medical.net     13 hrs ago          

Eli Lilly and Company has announced that it has completed the acquisition of SGX Pharmaceuticals, Inc. (Public, NASDAQ:SGXP), a San Diego-based biotechnology company focused on drug discovery and development in the area of...                    

comments

                   

Lilly Announces Completion of SGX Acquisition

redorbit.com     17 hrs ago   6 related          

INDIANAPOLIS, Ind., Aug. 20 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it has completed the acquisition of SGX Pharmaceuticals, Inc. , a San Diego-based biotechnology company focused on drug discovery...                    

comments

PDL Could Get $1.2B from BMS for Two Early Stage Antibodies

tmcnet.com     18 hrs ago   14 related          

710M for Elotuzumab After struggling through a year of shifting business strategies, PDL BioPharma Inc. signed an antibody deal with Bristol-Myers Squibb Co. that could be worth nearly $1.16 billion. The deal calls for New...                    

comments